|
LIVE WEBINAR: Thursday, April 22, 2021, 5:00 PM – 6:30 PM Eastern Time
Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers13th Annual Oncology Grand Rounds NCPD Webinar SeriesHodgkin and Non-Hodgkin Lymphomas
Faculty
Stephen M Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Rochester, Minnesota Carla Casulo, MD Associate Professor of Medicine Division of Hematology/Oncology Director, Hematology/Oncology Fellowship Program University of Rochester Wilmot Cancer Institute New York, New York John P Leonard, MD Richard T Silver Distinguished Professor of Hematology and Medical Oncology Senior Associate Dean for Innovation and Initiatives Executive Vice Chair, Joan and Sanford I Weill Department of Medicine Weill Cornell Medicine New York, New York Nurse Case Presentations By
Jacklyn Gideon, MSN, AGPCNP-BC Advanced Practice Provider Lead Apheresis APP Hematopoietic Cellular Therapy Program Section of Hematology/Oncology The University of Chicago Medicine and Biological Sciences Chicago, Illinois Robin Klebig, APRN, CNP, AOCNP Nurse Practitioner Assistant Professor of Medicine Division of Hematology Mayo Clinic Rochester, Minnesota Mollie Moran, APRN-CNP, AOCNP The James Cancer Hospital and Solove Research Institute The Ohio State University Columbus, Ohio Moderator Neil Love, MD Research To Practice Miami, Florida Thursday, April 22, 2021 Topics to Be Discussed
Target Audience
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCPD Designation Statements This educational activity for 1.5 contact hours is provided by RTP. This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours. To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity. Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/Lymphomas/ILNA Unlabeled/Unapproved Uses Notice There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Dr Casulo has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Ansell – Contracted Research to Institution: ADC Therapeutics SA, Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Oncology, Trillium Therapeutics Inc. Dr Leonard – Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Miltenyi Biotec, Regeneron Pharmaceuticals Inc, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech Foundation, Janssen Biotech Inc. CONTRIBUTING NURSES — Ms Gideon, Ms Klebig and Ms Moran had no relevant conflicts of interest to disclose. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc. RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Novartis and Seagen Inc. |